[Translation] A randomized, open, active-controlled trial to preliminarily evaluate the safety and immunogenicity of hepatitis A and B combined vaccine in healthy people aged 18 to 50 years

初步评价成人规格甲乙肝联合疫苗在18~50岁健康人中的安全性和免疫原性，为制定甲肝和乙肝联合免疫预防策略提供科学依据。

[Translation]

To preliminarily evaluate the safety and immunogenicity of the adult-specification hepatitis A and B combined vaccine in healthy people aged 18 to 50 years, and provide a scientific basis for the formulation of a combined hepatitis A and B immunization prevention strategy.

Start Date-

Sponsor / Collaborator

Sinovac Biotech Co. Ltd.

CTR20200473 / RecruitingPhase 1

甲型乙型肝炎联合疫苗（儿童规格）在成人和儿童中的开放性和幼儿中的随机、开放、阳性对照Ⅰ期临床试验

[Translation] A randomized, open-label, active-controlled phase I clinical trial of hepatitis A and B combined vaccine (pediatric specifications) in adults and children and in young children

初步评价儿童规格的甲乙肝联合疫苗在成人和儿童中的安全性、幼儿中的安全性和免疫原性。

[Translation]

To preliminarily evaluate the safety of pediatric-specification hepatitis A and B combined vaccine in adults and children, and its safety and immunogenicity in young children.

Start Date15 Apr 2020

Sponsor / Collaborator

Sinovac Biotech Co. Ltd.

100 Clinical Results associated with Combined hepatitis A and B vaccine(Sinovac Biotech Ltd.)

100 Translational Medicine associated with Combined hepatitis A and B vaccine(Sinovac Biotech Ltd.)

100 Patents (Medical) associated with Combined hepatitis A and B vaccine(Sinovac Biotech Ltd.)

162

Literatures (Medical) associated with Combined hepatitis A and B vaccine(Sinovac Biotech Ltd.)

11 Mar 2024·Human Vaccines & ImmunotherapeuticsQ3 · MEDICINE

Human papillomavirus (HPV) vaccination across a cascade of knowledge, willingness, and uptake among gay, bisexual, and other men who have sex with men in Canada’s three largest cities

Q3 · MEDICINE

Article

Author: Lachowsky, N. J. ; Lambert, G. ; Ogilvie, G. ; Grennan, T. ; Sauvageau, C. ; Jollimore, J. ; George, C. ; Tan, D. H. S. ; Hart, T. A. ; Grace, D. ; Gaspar, M. ; Yeung, A. ; Burchell, A. N. ; Coutlée, F. ; De Pokomandy, A. ; Moore, D. ; Cox, J. ; Nisenbaum, R. ; Grewal, R. ; Deeks, S. L.

BACKGROUNDSome Canadian jurisdictions offer publicly funded HPV vaccine to gay, bisexual, and other men who have sex with men (GBM) aged ≤26 years. We characterized factors associated with being in different stages of HPV vaccination.METHODSEngage is a sexual health study of GBM in the three largest Canadian cities recruited via respondent driven sampling (RDS). We categorized participants as: (1) unaware of HPV vaccine, (2) undecided/unwilling to get vaccinated, (3) willing to get vaccinated, (4) vaccinated with one or more doses. Our RDS-II weighted analyses used multinomial logistic regression to identify factors associated with being in earlier stages of the cascade compared to Stage 4.RESULTSAcross the cities, 26-40%, 7-14%, 33-39%, and 13-28% were in Stages 1 to 4, respectively. Compared to Stage 4, being in earlier stages of the cascade was associated with bisexual-identification (Stage 1: adjusted odds ratio[aOR] = 2.84, 95% confidence interval[CI] = 1.06-7.62; Stage 2: aOR = 3.09, 95%CI = 1.19-8.05), having immigrated to Canada (Stage 1: aOR = 1.79, 95%CI 1.07-2.99), preference to keep same-sex romantic relationships private (Stage 1: aOR = 1.25, 95% CI = 1.05-1.48; Stage 2: aOR = 1.24, 95%CI = 1.05-1.46), not receiving sexual health information (Stage 1: aOR = 0.31, 95% CI = 0.13-0.71; Stage 2: aOR = 0.27, 95%CI = 0.12-0.64), not accessing a health-care provider (Stage 2: aOR = 0.36, 95%CI = 0.15-0.83), and no past hepatitis A/B vaccination (Stage 1: aOR = 0.16, 95% CI = 0.09-0.30; Stage 2: aOR = 0.18, 95%CI = 0.09-0.35; Stage 3: aOR = 0.38, 95%CI = 0.21-0.61).DISCUSSIONInterventions are needed to reduce social and financial barriers, increase sexual health knowledge, and improve GBM-competent health-care access to increase vaccine uptake among GBM.

01 Mar 2023·Sexually Transmitted Infections

Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial

Letter

Author: Raffi, François ; Pialoux, Gilles ; Charreau, Isabelle ; Delaugerre, Constance ; Carette, Diane ; Gabassi, Audrey ; Capitant, Catherine ; Tremblay, Cécile ; Cotte, Laurent ; Spire, Bruno ; Le Turnier, Paul ; Molina, Jean-Michel ; Meyer, Laurence ; Chaix, Marie-Laure

Vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended in men who have sex with men (MSM). We assessed HAV and HBV vaccine uptake in the non-immune participants and their immunisation during follow-up of the ANRS IPERGAY (Intervention Préventive de l'Exposition aux Risques avec et pour les Gays) pre-exposure prophylaxis (PrEP) trial.During the ANRS IPERGAY trial among MSM (NCT 01473472), vaccination against HAV and HBV was offered free of charge to all non-immune participants at baseline. We assessed anti-HAV IgGs and anti-hepatitis B surface (HBs) antibodies (Abs) at baseline, 1–3 months after each vaccine dose and on the last follow-up visit. Vaccination uptake and immunisation were analysed in non-immune participants with at least 6 months of follow-up after the 1st vaccine dose.A total of 427 MSM with a median age of 34.8 years were analysed. Median follow-up was 2.2 years (Q1–Q3, 1.6–2.9). Absence of anti-HAV IgG at baseline (50.4%, 215/427) was associated with younger age (p=0.0001). Among HAV non-immune participants, 96.1% (197/205) received one or more vaccine doses and 91.0% (172/189) received two vaccine doses. Among HBV non-immune participants, 97.6 % (81/83) received one or more vaccine doses and 78.4% (58/74) received three doses. On the last-visit sample, anti-HAV IgG and anti-HBs Abs were respectively detected in 94.8% (95% CI 90.0% to 97.7%) and 79.6% (95% CI 66.5% to 89.4%) of participants with complete vaccination and in 80.0% (95% CI 51.9% to 95.7%) and 40.0% (95% CI 16.3% to 67.7%) of participants with incomplete vaccination.Vaccine acceptability against HAV and HBV infections was very high in MSM starting PrEP. Immunisation was high in participants with a full vaccination scheme. Physicians must consider PrEP visits as major opportunities to propose and complete HAV and HBV vaccination in at-risk non-immune subjects.

01 Jan 2023·PloS one

Cost-effectiveness of expanded hepatitis A vaccination among adults with diagnosed HIV, United States.

Article

Author: Tie, Yunfeng ; Van Handel, Michelle ; Nelson, Noele ; Abimbola, Taiwo O. ; Weiser, John ; Ouyang, Lijing

Hepatitis A virus can cause severe and prolonged illness in persons with HIV (PWH). In July 2020, the Advisory Committee on Immunization Practices (ACIP) expanded its recommendation for hepatitis A vaccination to include all PWH aged ≥1 year. We used a decision analytic model to estimate the value of vaccinating a cohort of adult PWH aged ≥20 years with diagnosed HIV in the United States using a limited societal perspective. The model compared 3 scenarios over an analytic horizon of 1 year: no vaccination, current vaccine coverage, and full vaccination. We incorporated the direct medical costs and nonmedical costs (i.e., public health costs and productivity loss). We estimated the total number of infections averted, cost to vaccinate, and incremental cost per case averted. Full implementation of the ACIP recommendation resulted in 775 to 812 fewer adult cases of hepatitis A in 1 year compared with the observed vaccination coverage. The incremental cost-effectiveness ratio for the full vaccination scenario was $48,000 for the 2-dose single-antigen hepatitis A vaccine and $130,000 for the 3-dose combination hepatitis A and hepatitis B vaccine per case averted, compared with the observed vaccination scenario. Depending on type of vaccine, full hepatitis A vaccination of PWH could lead to ≥80% reduction in the number of cases and $48,000 to $130,000 in additional cost per case averted. Data on hepatitis A health outcomes and costs specific to PWH are needed to better understand the longer-term costs and benefits of the 2020 ACIP recommendation.

100 Deals associated with Combined hepatitis A and B vaccine(Sinovac Biotech Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BC	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis A	CN	Sinovac Biotech Co. Ltd.	07 Jan 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B	Phase 1	CN	Sinovac Biotech Co. Ltd.	25 Mar 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| Vaccine	Not Applicable	-	300	combined hepatitis A and B vaccine (Group HAB_2D)	lcoejzrwpc(nfmfxyocxt) = No vaccine-related serious adverse events were reported nmmzojixay (ykewlygyve )	-	23 Aug 2010
				combined hepatitis A and B vaccine (Group HAB_3D)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Combined hepatitis A and B vaccine(Sinovac Biotech Ltd.)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation